ThyroidPrint®
Resolve Your Uncertainty

#KeepYourThyroid #DesignedToPredictBenign

The Thyroid Genetic Classifier to safely forgo unnecessary diagnostic thyroid surgery for indeterminate cytology

Up to 20% of thyroid nodule FNA biopsies are reported as indeterminate (Bethesda III/IV) following cytological examination. These nodules are managed through diagnostic surgery which is the standard approach. After surgery, up to 75% of these nodules are determined to be benign.[1] ThyroidPrint® reclassifies nodules as either benign or suspicious of malignancy, aiding decision-making, avoiding patients to undergo unnecessary surgeries, and reducing healthcare costs.

ThyroidPrint® clinical pathway in case of thyroid nodule detection

ThyroidPrint® accurately classifies indeterminate thyroid nodules with 95% NPV[2,3]



ThyroidPrint® Clinical Utility Study reduces unnecessary surgery by 67%[4]

Without ThyroidPrint®

SURGERY

AVOID SURGERY

With ThyroidPrint®



Idylla™ ThyroidPrint® Assay**

First-in-class cartridge-based assay for risk stratification of indeterminate thyroid nodules

For Research Use Only, not for use in diagnostic procedures

Idylla™ ThyroidPrint® Assay**

qPCR
of 10 genes

CXCR3, CXCL10, CCR3, CCR7, CXADR + TIMP1, CLDN1, KRT19, AFAP1L2, HMOX1

Tumor Inflammatory Microenvironment Genes

Tumor Epithelial Genes

Proprietary algorithm analysis

Idylla™ ThyroidPrint® **Result** reported as either **'HIGH'** or **'LOW'**

Unique sample-to-insight seamless workflow

Scan
Sample & Cartridge

Insert Sample
in the Cartridge

Insert Cartridge in the Idylla™ Platform
and obtain the result within 3 hours

(1) Haugen et al., 2015 American Thyroid Association Management guidelines for adult patients. Thyroid, 2016
(2) Gonzalez et al., A 10-Gene Classifier for Indeterminate Thyroid Nodules: Development and Multicenter Accuracy Study. Thyroid, 2017
(3) Zafereo et al., A Thyroid Genetic Classifier Correctly Predicts Benign Nodules with Indeterminate Cytology: Two Independent, Multicenter, Prospective Validation Trials. Thyroid, 2020
(4) Olmos et al., ThyroidPrint®: clinical utility for indeterminate thyroid cytology. End Rel Cancer, 2023

thyroidprint.com

GENEPRO DX
Transforming Precision Medicine

BIOCARTIS

Biocartis NV
Generaal De Wittelaan 11B
2800 Mechelen - Belgium
+32 15 632 888

Follow us on

www.biocartis.com
customerservice@biocartis.com

OUS.FL080.EN.R3.10/2024